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Abstract: Glycemic control (GC) has improved outcomes for intensive care unit (ICU) patients. However, 
the increased risk of hypoglycemia and glycemic variability due to inter- and intra- patient variability make 
safe, effective GC difficult. Stochastic TARgeted (STAR) GC framework is a unique, patient-specific, risk-
based dosing protocol directly accounting for both inter- and intra- patient variability using a stochastic 
model of future patient variability. A new tri-variate (3D) stochastic model, developed and validated in 
virtual trials to provide more accurate future predictions of insulin sensitivity (SI), is clinically evaluated.  
STAR-3D was implemented as standard care at the Christchurch Hospital ICU, New Zealand, between 
April 2019 and January 2021. In total, 567 patients (33276 hours) were treated. The overall median [IQR] 
BG achieved was 6.7 [6.0 7.8] mmol/L with 76% BG in the 4.4-8.0 mmol/L target band. Importantly, there 
were only 0.3% BG < 4.0 mmol/L (mild hypoglycemia) and no incidence of severe hypoglycemia (BG < 
2.2 mmol/L). These outcomes were achieved with median [IQR] 4.0 [2.0 6.0] U/h insulin and median [IQR] 
nutrition delivery of 99 [80 100]% goal feed (GF). Similar safety and performance BG outcomes were 
obtained at a per-patient level, suggesting STAR-3D successfully provided safe, effective control for all 
patients, regardless of patient condition. Compared to the original version of STAR, STAR-3D provided 
improved safety and efficacy, while achieving higher nutrition delivery. 
The new 3D stochastic model in STAR-3D provided higher safety and efficacy for all patients in this large 
clinical trial, despite using higher insulin rates than its predecessor to provide greater nutrition delivery. 
STAR-3D thus better captured patient-specific condition and variability to provide improved GC outcomes. 
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1. INTRODUCTION 
Patients admitted to critical care often experience stress-
induced hyperglycemia (McCowen et al., 2001), associated 
with increased mortality and morbidity (Krinsley, 2003). It is 
mainly driven by increased insulin resistance and excessive 
endogenous glucose production (McCowen et al., 2001). Early 
studies showed glycemic control (GC) is associated with 
improved outcomes in critically ill patients (Chase et al., 
2010a, Krinsley, 2004, Reed et al., 2007, Van den Berghe et 
al., 2001). However, other studies failed to replicate these 
results (Brunkhorst et al., 2008, Finfer et al., 2009, Finfer et 
al., 2012, Preiser et al., 2009), where the associated increased 
risk of hypoglycemia and glycemic variability, both associated 
with increased mortality and morbidity (Ali et al., 2008, 
Bagshaw et al., 2009, Egi et al., 2010, Krinsley et al., 2007), 
suggests GC is hard to achieve safely and effectively due to 
inter- and intra- patient variability (Chase et al., 2011a). 
More specifically, recent studies have shown GC protocols 
failing to achieve safe control for nearly all patient could 
mainly be due to protocol design rather the GC itself 
(Uyttendaele et al., 2017, Uyttendaele et al., 2019c). 
Importantly, glycemic outcome and mortality is a function of 
the quality of control achieved and not patient condition, 
showing the importance to provide safe, and effective control 
to all patients (Penning et al., 2015, Uyttendaele et al., 2017). 
GC protocols accounting for patient-specificity and ensuring 
high protocol compliance are thus needed (Chase et al., 2011b, 
Chase et al., 2011a, Chase et al., 2018a, Chase et al., 2018b, 
Chase et al., 2019, Uyttendaele et al., 2019c). 
The Stochastic TARgeted (STAR) GC framework is a unique 
model-based, patient-specific, and risk-based insulin dosing 
approach accounting for both inter- and intra- patient 
variability (Evans et al., 2012, Fisk et al., 2012). STAR uses a 
validated physiological model together with stochastic 
predictions to evaluate patient-specific risk of hyper- and 
hypo- glycemia for any given treatment (Lin et al., 2008, Lin 
et al., 2011). Uniquely, STAR modulates both insulin and 
nutrition inputs for increased quality of control while 
optimizing nutrition also (Stewart et al., 2016, Stewart et al., 
2018a, Uyttendaele et al., 2020a). STAR was independently 
proven safe and effective across cohorts and countries (Abu-
Samah et al., 2019, Stewart et al., 2016, Uyttendaele et al., 
2018a, Uyttendaele et al., 2019a, 2020a). 
Currently, STAR uses hourly identified model-based insulin 
sensitivity (SI) to forecast future likely variations in patient-
specific response to insulin, and mitigate risks accordingly 
(Lin et al., 2008). GC outcomes thus significantly rely on these 
predictions for control quality and outcomes. Previously, a 
more personalized 3D stochastic model using previous and 
current identified SI levels to forecast future SI was developed 
and simulated using validated virtual trials (Uyttendaele et al., 
2018b, Uyttendaele et al., 2019b). Results showed the 
potential ability of this new model to provide more 
personalized care by improving future SI forecasting and thus 
improved safety and efficacy in STAR compared to prior 
efforts using a lower dimensionality (Le Compte et al., 2010, 
Lin et al., 2006, Lin et al., 2008). Based on these encouraging 
results, a clinical trial using the new 3D stochastic model was 
implemented in the Christchurch Hospital Intensive Care Unit 
(ICU), New Zealand, where STAR is the standard of care. This 
study presents and compares preliminary results. 
2. METHODS 
2.1 STAR-3D protocol 
STAR is a model-based GC framework developed to provide 
patient-specific, risk-based GC (Evans et al., 2012, Fisk et al., 
2012, Lin et al., 2008, Lin et al., 2011). Time-varying, patient-
specific SI levels are identified from clinical data using a 
clinically validated physiological model, accounting for inter-
patient variability. SI characterizes patient-specific metabolic 
response to insulin, reflecting thus patient’s current metabolic 
state, which can differ for each patient despite similar levels of 
glycemia, insulin, and carbohydrate intake (Chase et al., 
2011a, Lin et al., 2011). 
Intra-patient variability is assessed using a stochastic model 
(Uyttendaele et al., 2018b, Uyttendaele et al., 2019b). This 
model uses tri-variate kernel-density methods on large 
population data to provide a 90% confidence interval of future 
variation of future SI based on previous and current SI levels 
(Davidson et al., 2019, Uyttendaele et al., 2018b, Uyttendaele 
et al., 2019b). Based on these predictions, STAR evaluates the 
corresponding likelihood of future blood glucose (BG) levels 
for any insulin and nutrition inputs, as depicted in Figure 1. 
This new 3D stochastic model was developed, tested, and 
validated in virtual trials showing improved prediction 
accuracy in SI variability, and, thus, the potential to add 
precision to STAR GC control and improve clinical outcomes 
(Chase et al., 2010b, Dickson et al., 2017, Uyttendaele et al., 
2018b, Uyttendaele et al., 2019b). 
STAR treatment recommendations are thus suggested based 
on predicted risks. STAR determines what combination of 
insulin and nutrition results in the 90% CI of predicted BG best 
overlapping the 4.4-8.0 mmol/L (80-145 mg/dL) target band 
(Evans et al., 2012). This always ensures a maximum risk of 
5% of predicted BG being below target, as safety is always 
ensured first. STAR currently offers up to three-hourly 
measurements option. However, 2- and 3- hourly interventions 
are not considered if no treatment option exists to ensure 
safety. 
In this clinical trial, patients were included after 2 consecutive 
BG assays > 8.0 mmol/L (145 mg/dL). Insulin boluses of 
maximum 6U can be administered intra-venously, with a 
maximum of 2U increments between intervention, and 
possible 3U/h additional infusion for highly resistive patients. 
Nutrition can be temporarily decreased by maximum 30% 
steps between interventions, down to a minimum of 30% of 
the original 100% goal feed (GF). GF is determined based on 
typical 25kcal/kg/day recommendations (Singer et al., 2019) 
and adjusted based on age, sex and weight. Typically nutrition 
is reduced if insulin only is not sufficient to safely decrease 
BG levels in highly insulin resistant patients. STAR will 
always try to maximize nutrition. In the event of hypoglycemia 
(BG < 3.0mmol/L), a dextrose bolus (10ml of 50% glucose) is 
directly administered and insulin stopped. In case of 
hypoglycemia, a new BG measurement within 1 hour is 
required. 
STAR is stopped if BG levels are stable (in target band) for at 
least 6 hours with total exogenous insulin rates ≤ 2U/h. It is 
important to note that patients can be included multiple times 
on STAR if their glycemia is dysregulated again after being 
stabilized. BG assays are taken using blood gas analyzer or 
glucometers, where typical reported measurement error in 
glucometers has minimal impact on decision making in the 
context of STAR (Uyttendaele et al., 2017). 
STAR is fully computerized and used on Android™ Tablets at 
patient bedside. Medical staff can easily enter BG, insulin, and  
 
 
Figure 1 - STAR uses stochastic models to forecast change in SI based on current SI value, and determines BG outcomes for 
given insulin and nutrition intervention. 
 
nutrition data directly in the tablet, and calculate a new 
treatment when required. Nurses are free to choose between 
the suggested 1-3 hour interval treatments and adapt rates 
according to their clinical judgment. This trial was 
implemented in the Christchurch Hospital ICU, New Zealand, 
as a clinical practice change and did not require ethics approval 
as the New Zealand Upper South Island Regional Ethics 
Committee approved the analysis and use of de-identified data 
as a clinical data audit. 
2.2 Protocol performance analysis 
Clinical trial data are analyzed to assess safety, efficacy, BG 
achieved, insulin and nutrition rates administered, and 
protocol workload. BG data is linearly interpolated and hourly 
resampled for each patient (Stewart et al., 2018b). Safety is 
assessed by percentage BG in mild hypoglycemia (% BG < 4.0 
mmol/L), in severe hypoglycemia (% BG < 2.2 mmol/L), and 
the number of patients experiencing severe hypoglycemia. 
Safety from hyperglycemia is assessed by the percentage BG 
in mild hyperglycemia (%BG > 8.0 mmol/L), and severe 
hyperglycemia (%BG > 10.0 mmol/L). Severe hyper- and 
hypo- glycemia are associated with increased mortality in ICU 
patients (Dungan et al., 2009, Egi et al., 2009, Egi et al., 2010, 
Finfer et al., 2012, Krinsley, 2005). 
Efficacy is assessed by %BG in target band (%BG in 4.4 – 8.0 
mmol/L) and by the median [IQR] BG level achieved. More 
specifically, high %BG in 4.4 - 8.0 mmol/L is associated with 
improved outcome in ICU patients (Chase et al., 2010a, 
Krinsley et al., 2015, Penning et al., 2014, Signal et al., 2012). 
Finally, workload is assessed by average BG measurements 
per day. Median insulin and nutrition rates are computed for 
each patient to assess patient-specific needs and how well they 
are met within glycemic control. 
3. RESULTS 
3.1 Patient Cohort 
In total, 787 patients were included in this trial between April 
2019 and January 2021. From these patients, 567 (72%) 
patients with GC episodes longer than 10 hours, average 
nutrition rates lower than 120% GF, and targeting the 4.4-8.0 
mmol/L target band are included in this analysis. These criteria 
ensure the normal per-protocol use of STAR and discard too 
short GC episodes or some that might have been specifically 
biased by medical staff. These 567 patients correspond to 
33276 hours of GC.  
In this cohort, 72% of patients are male, while the median 
[IQR] age is 65 [52 73] years old. These numbers are close to 
those typically seen in general ICU setting patients. 
Demographics are summarised in Table 1. 
3.2 Cohort Clinical results 
Cohort clinical trial results are presented in Table 2 and Figure 
2. In total, 19329 BG assays were taken, representing a 
workload of 14.0 measurements per day (one every 1.7 h). The 
median [IQR] BG achieved was 6.7 [6.0 7.8] mmol/L. STAR-
3D was highly effective, with more than 76% of hourly 
resampled BG within target band. 
STAR also provided highly safe control, with only 0.3% mild 
hypoglycemia and, importantly, no incidence of severe 
hypoglycemia. There was only 13.7% BG in mild 
hyperglycemia, and 9.1% in severe hyperglycemia. This 
highly safe, effective control was achieved with median [IQR] 
insulin of 4.0 [2.0 6.0], and median [IQR] dextrose rates 99 [80 
100] % GF. These carbohydrate intake rates do not consider 
21.4% of unfed hours based on clinical choice. 
Table 1 – Summary patient demographics 
 STAR-3D 
Number of patients 567 
Control hours (h) 33276 
Percent male (%) 72 
Age (years) 65 [52 73] 
 
Table 2 – Cohort clinical results. 
 STAR-3D 
Number of patients 567 
Hours of control (h) 33276 
Total BG measurements 19329 
Workload (measurements/day) 14.0 
BG (mmol/L) 6.7 [6.0 7.8] 
% BG in 4.4-8.0 mmol/L (%) 76.3 
% BG in 8.0 - 10.0 mmol/L (%) 13.7 
%BG > 10.0 mmol/L (%) 9.1 
% BG < 4.0 mmol/L (%) 0.3 
% BG < 2.2 mmol/L (%) 0 
Number of patient < 2.2 mmol/L 0 
Insulin rates (U/h) 4.0 [2.0 6.0] 
Total hours not fed (%) 21.4 
Dextrose rates excl. not fed hours 
(%GF) 
99 [80 100] 
Data is given as median [IQR] where appropriate. 
 
Figure 2 – Cohort BG (top), insulin (middle), and dextrose 
(bottom) rates achieved cumulative distribution functions. 
3.3 Per-patient clinical results 
Per-patient results are presented in Table 3. Per-patient results 
are important, as high GC performance must also importantly 
be achieved for all patients, and not only be good at a cohort 
perspective. Median [IQR] GC episode length was 1.6 [0.7 
3.1] days, and the median [IQR] starting BG was 10.9 [9.2 
13.4] mmol/L. Median [IQR] per-patient workload was 14.9 
[12.5 17.5] measurements per day. The median [IQR] median 
BG achieved was 6.7 [6.2 7.4] mmol/L, with 79 [60 89] %BG 
within target band. 
Table 3 – Per-patient clinical results. 
 STAR-3D 
Number of patients 567 
Episode length (days) 1.6 [0.7 3.1] 
Starting BG (mmol/L) 10.9 [9.2 13.4] 
Workload (measurements/day) 14.9 [12.5 17.5] 
Median BG (mmol/L) 6.7 [6.2 7.4] 
% BG in 4.4-8.0 mmol/L (%) 79 [60 89] 
% BG in 8.0 - 10.0 mmol/L (%) 11 [6 19] 
%BG > 10.0 mmol/L (%) 6 [0 18] 
% BG < 4.0 mmol/L (%) 0 [0 0] 
% BG < 2.2 mmol/L (%) 0 [0 0] 
Number of patient < 2.2 mmol/L 0 
Median insulin rates (U/h) 4.0 [2.5 5.0] 
Patients with nutrition (%) 68 
Median dextrose rates excl. 
patients not fed (%GF) 
97 [71 100] 
Data is given as median [IQR] where appropriate. 
In terms of safety, median [IQR] %BG < 4.0 mmol/L as well 
as %BG < 2.2 mmol/L was 0 [0 0]%, with no patient 
experiencing severe hypoglycemia. The median [IQR] per-
patient %BG in 8.0-10.0 mmol/L and % BG > 10.0 mmol/L 
was 11 [6 19]% and 6 [0 18]%, respectively. 
These results were achieved with median [IQR] per-patient 
median insulin rates of 4.0 [2.5 5.0] U/h and median [IQR] 97 
[71 100] %GF nutrition rates. Only 32% (180) of patients did 
not receive nutrition during GC. 
4. DISCUSSION 
This trial was implemented following encouraging results 
showing STAR-3D, using a new 3D, tri-variate stochastic 
model to better account for changes in identified patient-
specific insulin sensitivity, could significantly improve GC 
outcomes (Uyttendaele et al., 2018b, Uyttendaele et al., 
2019b). More specifically, improving prediction of future SI 
levels improves the assessment of hypoglycemic risk 
associated with any specific treatment, thus improving BG 
outcomes, GC, and, as a result, outcomes. 
Overall, STAR-3D provided highly effective control (76.3% 
BG in band and 79 [60 89] per-patient %BG in band) and very 
high safety with no incidence of severe hypoglycemia (and 
very low 0.3% overall incidence of mild hyperglycemia). The 
6.7 [6.0 7.8] mmol/L cohort BG and the per-patient 6.7 [6.2 
7.4] mmol/L median BG show how STAR-3D successfully 
managed to control BG to beneficial ranges. Importantly, 
while STAR-3D provided high quality control at a cohort 
perspective, these observations are all true at a per-patient 
perspective, showing STAR-3D provides high quality control 
to all patients, thanks to its patient-specific, risk-based dosing 
approach. Altogether, these outcomes are all associated with 
improved outcomes ICU patients (Ali et al., 2008, Chase et al., 
2010a, Egi et al., 2006, Egi et al., 2010, Krinsley, 2005, 
Mesotten et al., 2009, Van den Berghe et al., 2006). 
In addition, STAR-3D was able to provide very high nutrition 
rates (99 [80 100] %GF for the overall cohort, 97 [71 
100]%GF at per-patient level). These high, patient-specific 
nutrition rates achieved are close to best ICU settings in the 
world (Stewart et al., 2018a), despite remaining in safe BG 
ranges, and thus likely avoiding both over- and under- feeding. 
The workload required to achieve these high performance and 
safety levels (14.0 measures per day, 14.9 [12.5 17.5] 
measures per day per-patient) may seem higher than most 
protocols only measuring every 4 hours. It is higher than the 
12 measurements per day observed in the original version of 
STAR using a 2D stochastic model (Stewart et al., 2016). 
However, this trial shows similar to higher efficacy and higher 
safety, despite the  higher insulin and nutrition rates achieved. 
This result thus suggests the 3D stochastic model, with 
improved prediction, better accounts for patient-specificity 
and provides safer, more effective control with more nutrition 
intake, but at the cost of slightly higher workload.  
Finally, for context, it is very important to mention the starting 
BG in this trial is significantly higher than the value reported 
using the original version of STAR, which can clearly affects 
the slightly higher median BG achieved and the increased 
workload (Stewart et al., 2016). This issue is compounded by 
the reduced time on GC due to improved control. In a previous 
study, virtual trials showed workload could be reduced by 
increasing measurement intervals up to 6 hours, but would 
imply a trade-off between workload, safety, and nutrition 
intake (Uyttendaele et al., 2020b). However, overall, these 
results and slightly increased workload are likely anomalies of 
the reduced time on GC and improved control, where GC is 
halted when time in band is high and insulin is low. 
5. CONCLUSIONS 
The new 3D stochastic model used in STAR expectedly 
enabled greater patient-specific control, and provided highly 
safe, effective control to all patients. STAR-3D also provided 
higher nutrition delivery compared to its predecessor. These 
outcomes likely suggest improved patient outcome as the 
higher safety, efficacy, nutrition delivery achieved in this trial 
are all associated with improved outcome in ICU patients, but 
more analyses are needed to confirm this statement. 
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